Welcome, Guest. Please login or register.
July 14, 2024, 12:14:25 am

Login with username, password and session length

  • Total Posts: 55130
  • Total Topics: 4851
  • Online Today: 44
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 54
Total: 54


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Treating HIV Early Lowers Liver Fibrosis Risk  (Read 7602 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Treating HIV Early Lowers Liver Fibrosis Risk
« on: January 04, 2019, 10:40:03 am »
Starting antiretroviral (ARV) treatment for HIV when CD4s are still high reduces the risk of liver fibrosis compared with waiting to start ARVs until the immune system has deteriorated somewhat, aidsmap reports. This holds true even among people without hepatitis B or C virus (HBV/HCV).

Publishing their findings in the journal Hepatology, researchers conducted an analysis from the global START trial, a randomized controlled study that enrolled people with HIV who had a CD4 count greater than 500 and randomized them to start ARVs immediately or wait until their CD4s had dropped below 350.

For more...


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.